NCT00409994View on ClinicalTrials.gov

Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

August 3, 2018

Study Completion Date

December 31, 2018

Conditions
Rectum Cancer
Interventions
DRUG

Rapamycin

dosis escalation: 2/4/6 mg rapamycin tablets, once daily during 13 days

Trial Locations (1)

6202 AZ

Maastricht Radiation Oncology, Maastricht

All Listed Sponsors
collaborator

Academisch Ziekenhuis Maastricht

OTHER

lead

Maastricht Radiation Oncology

OTHER

NCT00409994 - Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer | Biotech Hunter | Biotech Hunter